Loading news...
Acuitas Investments LLC bought a new position in Tetra Technologies, Inc. (NYSE: TTI) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor bought 736,170 shares of the oil and gas company's stock, valued at approximately $4,233,000. Tetra Technologies makes up approximately
SPRING, Texas, March 4, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced that Brady Murphy, Chief Executive Officer; Elijio Serrano, Chief Financial Officer; and Kurt Hallead, VP of Investor Relations and Treasurer, will be hosting one-on-one meetings with institutional investors on March 17, 2026 during the Piper Sandler 26th Annual Energy Conference in Las Vegas. Investors interested in scheduling one-on-ones meetings at the conference should contact their Piper Sandler sales representative.
TETRA Technologies, Inc. (TTI) Q4 2025 Earnings Call Transcript
SPRING, Texas, Feb. 25, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced financial results for the three and twelve months ended December 31, 2025. Fourth-Quarter 2025 Financial Highlights Revenues of $146.7 million increased 9% from the fourth quarter of 2024 Loss from continuing operations was $15.3 million, inclusive of $18.7 million of unusual charges Loss per share from continuing operations was $0.11 while Adjusted net income per share was $0.02, excluding unusual charges Adjusted EBITDA was $20.4 million Net cash provided by operating activities was $31.7 million - materially above the prior sequential quarter and the fourth quarter of 2024; Adjusted free cash flow was $3.1 million and base business adjusted free cash flow was exceptionally strong at $21.8 million.
Tetra Technologies (NYSE: TTI - Get Free Report) is projected to post its Q4 2025 results after the market closes on Wednesday, February 25th. Analysts expect Tetra Technologies to post earnings of $0.03 per share and revenue of $140.9750 million for the quarter. Interested persons can find conference call details on the company's upcoming Q4 2025
San Diego, California--(Newsfile Corp. - February 2, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare pediatric diseases, today provided an update on its nephropathic cystinosis program and announced a new investigator-initiated study (IIS) collaboration with Dr. Larry Greenbaum, a recognized global leader in cystinosis research, at Emory University and Children's Healthcare of Atlanta. The IIS will evaluate Thiogenesis' lead product candidate, TTI-0102, a next-generation cysteamine-based prodrug, in patients with nephropathic cystinosis to further characterize once-daily dosing, tolerability, and white blood cell (WBC) cystine control across a representative patient population.
SPRING, Texas, Feb. 2, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) will release Fourth Quarter and Full Year 2025 results after the market close on Wednesday, February 25, 2026 and will host a conference call at 10:30 a.m. Eastern Time on Thursday, February 26, 2026.
Tetra Technologies, Inc. (NYSE: TTI - Get Free Report) passed above its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $6.87 and traded as high as $12.00. Tetra Technologies shares last traded at $11.5710, with a volume of 1,574,119 shares changing hands. Wall Street Analysts Forecast Growth A
Acuitas Investments LLC acquired a new stake in Tetra Technologies, Inc. (NYSE: TTI) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,180,424 shares of the oil and gas company's stock, valued at approximately $6,787,000. Tetra Technologies makes up about 2.9% of Acuitas
Sold 384,274 shares of TETRA Technologies; estimated transaction value $2.96 million (based on quarterly average pricing). Quarter-end position value declined by $1.1 million, reflecting both trading and stock price changes.
Summary Stone House Investment Management, LLC initiated a new position in Tetra Technologies Inc(TTI), purchasing 4,190 shares valued at approximately
Pre-Market Stock Futures: The futures are trading lower again after a dreadful risk-off day across Wall Street, where all major indices finished the day solidly lower. The combination of President Trump's pursuit of Greenland, multiple geopolitical hotspots, both foreign and domestic, and a market that remains very overbought led to the biggest selling day we... Here Are Wednesday's Top Wall Street Analyst Research Calls: Alibaba, Applied Digital, ARM Holdings, FedEx, Flutter Entertainment, Ulta Beauty, and More.
San Diego, California--(Newsfile Corp. - January 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced that an abstract outlining preliminary results from its Phase 2 clinical trial of TTI-0102 for Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) in the EU has been accepted as Late-Breaking News for presentation at the Mitocon Conference 2026, which will take place in Pisa from January 23-26, 2026. The poster entitled, "Pharmacokinetics and Pharmacodynamics of TTI-0102 in MELAS," will be presented during the Poster Session on January 23rd, and will summarize preliminary pharmacokinetic and pharmacodynamic findings from Thiogenesis' Phase 2 MELAS study.
SPRING, Texas, Jan. 7, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced that its senior management will be participating in the following investor conferences. 28th Annual Needham Growth Conference Elijio Serrano, Chief Financial Officer, and Matt Sanderson, Chief Commercial Officer, will be participating in the 28th Annual Needham Growth Conference in New York City on January 13, 2026.
Dr. Rioux Will Present on Phase 2 MELAS Program & Upcoming Phase 2a Leigh Syndrome Trial San Diego, California--(Newsfile Corp. - January 5, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced that its Chief Executive Officer, Patrice Rioux, MD, Ph.D., will participate as a panelist in the United Mitochondrial Disease Foundation's ("UMDF") 2026 Bench-to-Bedside webinar on January 5, 2026.
SPRING, Texas , Dec. 9, 2025 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE: TTI) announced that its senior management will be participating in the following investor conferences. Jefferies 11th Annual Virtual Storage and Battery Conference Elijio Serrano, Chief Financial Officer, and Kurt Hallead, VP of Investor Relations and Treasurer, will be participating in a fireside chat on December 11, 2025, between 2:25pm et and 3:00pm et.
Critical mineral extraction represents another key step in ONE TETRA 2030 strategy SPRING, Texas , Dec. 2, 2025 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced today that it has signed a term sheet outlining key parameters to form a joint venture with Magrathea Metals, Inc. (a private company developing innovative technology for producing clean, secure magnesium metal from seawater and brines) to rebuild America's magnesium metal defense industrial base at TETRA's Evergreen Project in Southwest Arkansas. Magnesium is the "gateway metal" used across the defense industrial base and economy and is designated a critical mineral by the Department of Energy, Department of War, and Department of the Interior.
Tetra Technologies (NYSE: TTI - Get Free Report) and Core Laboratories (NYSE: CLB - Get Free Report) are both small-cap energy companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends and institutional ownership. Insider and Institutional Ownership 70.2% of Tetra
SPRING, Texas , Dec. 1, 2025 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced that Brady Murphy, Chief Executive Officer, and Kurt Hallead, VP of Investor Relations and Treasurer, will be hosting one-on-one meetings with institutional investors on December 10, 2025 at the Wells Fargo 24th Annual Energy & Power Symposium at the Westin Times Square in New York City. Investors interested in scheduling one-on-ones meetings at the conference should contact their Wells Fargo sales representative.
IND expected in early 2026; TTI-0102 designed to improve tolerability & simplify dosing San Diego, California--(Newsfile Corp. - November 24, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced plans to initiate a Phase 3 pivotal clinical trial of its lead compound TTI-0102 for the treatment of nephropathic cystinosis, an inherited lysosomal storage disorder requiring lifelong cystine-depleting therapy. The Company plans to submit an Investigational New Drug (IND) application in early 2026.